October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Mehdi Hamadani: Efficacy of axatilimab in chronic graft-versus-host disease
Sep 26, 2024, 14:27

Mehdi Hamadani: Efficacy of axatilimab in chronic graft-versus-host disease

Mehdi Hamadani shared a post on X, about recent paper published in The New England Journal of Medicine:

Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.

Authors: Daniel Wolff, Corey Cutler, Stephanie J. Lee, Iskra Pusic, Henrique Bittencourt, Jennifer White, Mehdi Hamadani, Sally Arai, Amandeep Salhotra, Jose A. Perez-Simon, Amin Alousi, Hannah Choe, Mi Kwon, Arancha Bermúdez, Inho Kim, Gerard Socié, Saurabh Chhabra, Vedran Radojcic, Timothy O’Toole, Chuan Tian, Peter Ordentlich, Zachariah DeFilipp, Carrie L. Kitko.

Mehdi Hamadani

“AGAVE 201 out in the New England Journal of Medicine. Remarkable efficacy of axatilimab (blocking colony-stimulating factor 1 receptor) in chronic graft-versus-host disease. I have observed some phenomenal response on trial.

  • Look for puffy eyes.
  • Artifact elevation of aspartate aminotransferase/alanine aminotransferase/amylase/lipase due to inhibition of Kupffer cells.”

Source: Mehdi Hamadani/X

Mehdi Hamadani is a Professor of Internal Medicine at the Medical College of Wisconsin, where he also serves as Director of the Blood and Marrow Transplant (BMT) and Cellular Therapy Program. Additionally, he is the Associate Scientific Director at the Center for International Blood and Marrow Transplantation Research. He holds leadership roles within the American Society for Transplantation and Cellular Therapy (ASTCT), including Secretary and Co-Chair of its scientific journal.